NONCONTRACEPTIVE BENEFITS OF DROSPIRENONE-CONTAINING ORAL CONTRACEPTIVES: NEW OPPORTUNITIES


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Objective. To carry out a systems analysis of the data available in the current literature on the antimineralocorticoid and antiandrogenic effects of a combined oral contraceptive (COC) pill containing 20 ßg ethinyl estradiol (EE) and 3 mg drospirenone (DRSP) in a 24/4 regimen. Material and methods. The review includes the foreign and Russian publications available in the Pubmed database on this topic. The search depth was 15 years. Results. The paper describes the mechanisms of the antimineralocorticoid and antiandrogenic effects of the combination of 20 μg EE and 3 mg DRSP and presents data on its efficacy in patients with premenstrual syndrome and premenstrual dysphoric disorder PMS/PMDD, as well as with androgen excess-related diseases and acne. Conclusion. The combination of 20 μg EE and 3 mg DRSP, that of the low-dose estrogen and the highly selective progestogen with antimineralocorticoid and antiandrogenic properties, at a short hormone-free interval is optimal for patients with hyperandrogenism, acne, and PMS/PMDD.

Full Text

Restricted Access

About the authors

Elena E. Grodnitskaya

Center for Family Planning and Reproduction, Moscow Healthcare Department

Email: elena1778@mail.ru
MD, PhD Moscow 117209, Sevastopolsky Avenue 24А Russia

References

  1. Machado R.B., Pompei L. de M., Giribela A.G., Giribela C.G. Drospirenone/ ethinylestradiol: a review on efficacy and noncontraceptive benefits. Womens Health (Lond.). 2011; 7(1): 19-30. doi: 10.2217/whe.10.84.
  2. Шарапова О.В., Кулаков В.И., Стрижаков А.Н. Современные методы профилактики абортов. Научно-практическая программа. М.: Министерство здравоохранения Российской Федерации, Международный фонд охраны здоровья матери и ребенка; 2004.
  3. Losert W., Casals-Stenzel J., Buse M. Progestogens with antimineralocorticoid activity. Arzneimittelforschung. 1985; 35(2): 459-71.
  4. Perez-Lopez F.R. Clinical experiences with drospirenone: from reproductive to postmenopausal years. Maturitas. 2008; 60(2): 78-91.
  5. Reid R.L. Premenstrual syndrome. In: De Groot L.J., Beck-Peccoz P., Chrousos G., Dungan K., Grossman A., Hershman J.M. et al., eds. Endotext [Internet]. South Dartmouth (MA): MDText.com Inc.; 2000-. Last Update: June 30, 2014.
  6. Hantsoo L., Epperson C.N. Premenstrual dysphoric disorder: epidemiology and treatment. Curr. Psychiatry Rep. 2015; 17(11): 87. doi: 10.1007/s11920-015-0628-3.
  7. Lopez L.M., Kaptein A.A., Helmerhorst F.M. Oral contraceptives containing drospirenone for premenstrual syndrome. Cochrane Database Syst. Rev. 2012; (2): CD006586. doi: 10.1002/14651858.CD006586.
  8. Sulak P.J., Scow R.D., Preece C., Riggs M.W., Kuehl T.J. Hormone withdrawal symptoms in oral contraceptive users. Obstet. Gynecol. 2000; 95(2): 261-6.
  9. Fu Y., Mi W., Li L., Zhang H., Wang J., Cheng W. et al. Efficacy and safety of a combined oral contraceptive containing drospirenone 3 mg and ethinylestradiol 20 |ig in the treatment of premenstrual dysphoric disorder: a randomized, double blind placebo-controlled study. Zhonghua Fu Chan Ke Za Zhi. 2014; 49(7): 506-9.
  10. Pearlstein T.B., Bachmann G.A., Zacur H.A., Yonkers K.A. Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation. Contraception. 2005; 72(6): 414-21.
  11. Yonkers K.A., Brown C., Pearlstein T.B., Foegh M., Sampson-Landers C., Rapkin A. Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder. Obstet. Gynecol. 2005; 106(3): 492-501.
  12. Oettel M., Carol W., Elger W. et al. A 19-norprogestin without a 17alpha-ethinyl group. II: dienogest from a pharmacodynamic point of view. Drugs Today. 1995; 31(7): 517-36.
  13. Koltun W., Lucky A.W., Thiboutot D., Niknian M., Sampson-Landers C., Korner P., Marr J. Efficacy and safety of 3 mg drospirenone/20 mcg ethinylestradiol oral contraceptive administered in 24/4 regimen in the treatment of acne vulgaris: a randomized, double-blind, placebo-controlled trial. Contraception. 2008; 77(4): 249-56. doi: 10.1016/j.contraception.2007.11.003.
  14. Lucky A.W., Koltun W., Thiboutot D., Niknian M., Sampson-Landers C., Korner P., Marr J. A combined oral contraceptive containing 3-mg drospirenone/ 20-microg ethinyl estradiol in the treatment of acne vulgaris: a randomized, double-blind, placebo-controlled study evaluating lesion counts and participant self-assessment. Cutis. 2008; 82(2): 143-50.
  15. Maloney J.M., Dietze P. Jr., Watson D., Niknian M., Lee-Rugh S., Sampson-Landers C., Korner P. A randomized controlled trial of a low-dose combined oral contraceptive containing 3 mg drospirenone plus 20 microg ethinylestradiol in the treatment of acne vulgaris: lesion counts, investigator ratings and subject self-assessment. J. Drugs Dermatol. 2009; 8(9): 837-44.
  16. Palli M.B., Reyes-Habito C.M., Lima X.T., Kimball A.B. J A single-center, randomized double-blind, parallel-group study to examine the safety and efficacy of 3mg drospirenone/0.02 mg ethinyl estradiol compared with placebo in the treatment of moderate truncal acne vulgaris. J. Drugs Dermatol. 2013; 12(6): 633-7.
  17. Beck J.I., Boothroyd C., Proctor M. Oral anti-oestrogens and medical adjuncts for subfertility associated with anovulation. Cochrane Database Syst. Rev. 2005; (1): CD002249.
  18. Martin K.A., Chang R.J., Ehrmann D.A., Ibanez L., Lobo R.A., Rosenfield R.L. et al. Evaluation and treatment of hirsutism in premenopausal women: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 2008; 93(4): 1105-20.
  19. Batukan C., Muderris I.I., Ozcelik B., Ozturk A. Comparison of two oral contraceptives containing either drospirenone or cyproterone acetate in the treatment of hirsutism. Gynecol. Endocrinol. 2007; 23(1): 38-44.
  20. Oner G., Muderris I.I. A prospective randomized trial comparing low-dose ethinyl estradiol and drospirenone 24/4 combined oral contraceptive vs. ethinyl estradiol and drospirenone 21/7 combined oral contraceptive in the treatment of hirsutism. Contraception. 2011; 84(5): 508-11. doi: 10.1016/j. contraception.2011.03.002.
  21. ESHRE Capri Workshop Group. Hormones and cardiovascular health in women. Hum. Reprod. Update. 2006; 12(5): 483-97.
  22. Romualdi D., De Cicco S., Busacca M., Gagliano D., Lanzone A., Guido M. Clinical efficacy and metabolic impact of two different dosages of ethinylestradiol in association with drospirenone in normal-weight women with polycystic ovary syndrome: a randomized study. J. Endocrinol. Invest. 2013; 36(8): 636-41.
  23. Fruzzetti F., Perini D., Lazzarini V., Parrini D., Gambacciani M., Genazzani A.R. Comparison of effects of 3 mg drospirenone plus 20 mg ethinyl estradiol alone or combined with metformin or cyproterone acetate on classic metabolic cardiovascular risk factors in nonobese women with polycystic ovary syndrome. Fertil. Steril. 2010; 94(5): 1793-8. doi: 10.1016/j.fertnstert.2009.10.016.
  24. Caprio M., Antelmi A., Chetrite G., Muscat A., Mammi C., Marzolla V. et al. Antiadipogenic effects of the mineralocorticoid receptor antagonist drospirenone: potential implications for the treatment of metabolic syndrome. Endocrinology. 2011; 152(1): 113-25. doi: 10.1210/en.2010-0674.
  25. Bachmann G., Sulak P.J., Sampson-Landers C., Benda N., Marr J. Efficacy and safety of a low-dose 24-day combined oral contraceptive containing 20 micrograms ethinylestradiol and 3 mg drospirenone. Contraception. 2004; 70(3): 191-8.
  26. Naessén S., Carlström K., Byström B., Pierre Y., Hirschberg A.L. Effects of an antiandrogenic oral contraceptive on appetite and eating behavior in bulimic women. Psychoneuroendocrinology. 2007; 32(5): 548-54.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies